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In view of the experimental evidence suggesting that the micronutrient selenium reduces prostate cancer risk, we investigated the
association between the selenium level in fingernails, a measure of long-term selenium intake, and prostate cancer risk in a
case–control study among 656 British men, conducted in 1989–1992. Nail clippings were taken at the time of recruitment and
selenium concentration, measured using neutron activation techniques, was successfully assayed for 300 case–control pairs and
varied six-fold among the controls (0.59p.p.m.; interquartile range, 0.50–0.71p.p.m.). Nail selenium concentration was not
significantly associated with prostate cancer risk: men in the highest quartile of nail selenium had a slightly increased risk compared
with men in the lowest quartile (OR 1.24, 95 CI, 0.73–2.10); for advanced prostate cancer, men in the highest quartile had a slightly
reduced risk compared with men in the lowest quartile (OR 0.78, 95% CI, 0.27–2.25). These results suggest that selenium is not
strongly associated with prostate cancer risk in British men.
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Selenium is an essential trace element found largely in grains, fish
and meat products and has been shown to have antioxidant and
other potentially anticarcinogenic properties (Combs and Gray,
1998). Experimental evidence indicates that selenium supplemen-
tation can reduce the incidence of viral and chemically induced
tumours in animals (Vernie, 1984), including prostate cancer cell
lines (Menter et al, 2000).
The selenium content in foods varies widely between regions
(Levander, 1987) because it is largely determined by the amount of
selenium in the soil. Ecological data suggest that regional cancer
mortality rates in the United States are inversely correlated with
the selenium concentration in plants (Clark et al, 1991), and a
randomised controlled trial among skin cancer patients found
selenium supplementation of 200mgday
 1 to be associated with a
significant 63% reduction in prostate cancer incidence (Clark et al,
1996; Duffield-Lillico et al, 2002). However, little is known about
the relationship between the selenium status and prostate cancer
risk in the general population.
The aim of this study is to investigate the association between
nail selenium concentration, a marker of long-term intake, and
prostate cancer risk. A subsidiary aim is to examine whether
factors that may influence selenium status, such as smoking
(Hunter et al, 1990), vitamin E intake (Diplock, 1978) or the
aggressiveness of disease at the time of recruitment (Yoshizawa
et al, 1998; Goodman et al, 2001) modify the association between
selenium concentration and prostate cancer risk.
SUBJECTS AND METHODS
A population-based case–control study of the association between
diet and prostate cancer was established in Britain, between 1989
and 1992, and included 328 men with incident prostate cancer and
328 population-based controls (Key et al, 1997). The study was
restricted to white men under the age of 75 years who could speak
English and who were well enough to complete a diet interview and
give a reasonable history. Identification of cases was by searching
appropriate medical records and cancer registries throughout
Oxfordshire, West Berkshire and Leeds; the study was approved by
the local ethics committees in these areas. The date of diagnosis
was taken as the date on the histopathology report or the date of
the first letter from the consultant giving a diagnosis of prostate
cancer. Cases were classified as having advanced prostate cancer if
there was radiological or histopathological evidence of local
invasion and/or metastases to the bone or soft tissue. Controls
were taken from the patient list of the general practitioner of each
case and were matched on age (within 1 year) and region of
residence. Men who had a previous diagnosis of prostate cancer or
who had had a radical prostatectomy were not eligible as controls.
One control was selected for each case, based either on the closest
date of birth (for practices with computerised records) or on
alphabetical order of surname after omitting the first 10 patients
following the case (for practices without computerised records). Of
the 425 eligible cases identified, 328 were interviewed (77.2%), 33
refused (7.8%), for 28 the general practitioner had advised against
contact (6.6%), 34 had died before an interview could be obtained
(8.0%) and two had emigrated outside the study area (0.5%). Of
the first 328 controls selected, 267 agreed to be interviewed
(81.4%), 42 refused (12.8%) and for 19 the consultant or general
practitioner had advised against contact (5.8%). Informed written
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yconsent was obtained from each of the study subjects. All men
were interviewed by one of three female interviewers, who also
took fingernail clippings at the same time as completion of the
interview. The same interviewer covered all the cases and controls
in each of the three health districts. In total, 93% of cases were
interviewed within 1 year of diagnosis (median interval of 4
months).
All participants completed a questionnaire that included details
of age, anthropometric, smoking and other lifestyle factors as well
as a detailed semiquantitative food-frequency questionnaire that
assessed intake of 83 food items during the last 5 years. Study
participants were invited to contribute fingernail clippings, of
which 632 (96%) did so. Nail clippings were kept in an envelope
marked with a unique study identification number and stored at
room temperature until analysis. The selenium content was
assayed using instrumental neutron activation analysis techniques
at the University of Missouri-Columbia Research Reactor Center,
Columbia, USA. Case and control specimens were analysed within
the same batch in random order and laboratory personnel were
blinded to the case–control status of each individual. Nail
clippings were thoroughly washed with de-ionised water and
freeze-dried. Specimens were irradiated with neutrons and
transferred to a high-resolution gamma-ray spectrometer where
the gamma-ray from the decay of
77mSe was quantified and
selenium concentrations were determined by standard compar-
ison. For 94 subjects, there was adequate sample to prepare and
analyse at least two replicate subsamples to check sample
homogeneity and analytical reproducibility. A mean and standard
deviation was calculated for each replicate. The average relative
standard deviation of the mean for these 94 replicate sets was 4.1%.
A Standard Reference Material, supplied by the National Institutes
of Standards and Technology (NIST SRM 1577 Bovine Liver)
having a certified selenium concentration (1.170.1p.p.m.) was
analysed with each sample batch. In total, 24 aliquots of NIST SRM
1577 were analysed giving a relative standard deviation of the
mean of 3.3%.
Statistical analysis
Since the distributions of nail selenium values and dietary intakes
were skewed toward the higher levels, these values were naturally
logarithmically transformed to approximate a normal distribution.
The means and their corresponding 95 percent confidence
intervals (95% CI) are presented as back-transformed values.
Comparisons of the geometric mean nail selenium concentration
by sociodemographic and lifestyle variables were examined using
analysis of variance. Comparison of the mean selenium concen-
tration by case–control status was examined using the paired t-
test and analysis of variance, where appropriate. Selenium values
were categorised into fourths based on the distribution among the
control subjects and the association between nutrient intake and
selenium concentration was assessed using one-way analysis of
variance. Relative risks were estimated as odds ratios (with their
corresponding 95% CIs) using conditional logistic regression
techniques and potential confounders were included as covariates
in the models. Odds ratios for each quartile were calculated using
the lowest fourth as the referent category. Where appropriate, a
test for linear trend was performed to assess statistical significance
across exposure categories by including the median value of each
quartile among the controls as a continuous variable in the models.
All P-values were based on two-tailed tests and a value of less than
0.05 was considered statistically significant. Interaction effects
were examined between the selenium status and the aggressiveness
of the disease, smoking and vitamin E intake. For the latter
analysis, selenium concentration and vitamin E intake were
categorised into two groups according to the median concentration
among the controls. Interaction effects were assessed by the
likelihood ratio test for the interaction term added to a model that
also included the variables as separate factors. All analyses were
conducted using Stata version 8.0 (Statacorp, 2003).
RESULTS
Out of the 656 study participants, 24 subjects did not provide nail
samples (17 cases; seven controls) and five subjects had selenium
values that remained very high after repeated laboratory analysis
(range 4.6–35.1p.p.m.) and were thus excluded from subsequent
statistical analysis (one case; four controls). In total, 300 case–
control pairs were available for analysis.
The mean age at the time of recruitment was 68.6 for cases and
68.3 for controls and ranged from 44 to 77 years. Among the 300
controls, selenium values ranged six-fold from 0.354 to
2.102p.p.m. with a median concentration of 0.593p.p.m. and an
interquartile range of 0.498–0.705p.p.m. Table 1 shows the
geometric mean selenium concentration according to baseline
characteristics among the 300 control subjects. The mean nail
selenium concentration differed significantly by region, being
highest in men recruited from Oxfordshire and lowest in men
recruited from the Leeds region (test for heterogeneity; Po0.0001).
However, adjustment for age group, smoking status and total
energy intake reduced the differences in nail selenium concentra-
tion among the three regions (P¼0.06; results not shown).
Smoking was significantly associated with nail selenium concen-
tration, with current smokers having, on average, a 14% lower
selenium concentration than never smokers and a 10% lower
concentration than past smokers (test for heterogeneity:
Table 1 Geometric mean selenium concentration according to baseline
characteristics among 300 controls
Variable Number
Mean Se
concentration P-value
Age (years)
o60 17 0.690
60–69 124 0.600
70+ 159 0.612 0.15
Region
Oxfordshire 102 0.643
West Berkshire 109 0.614
Leeds 89 0.573 o0.0001
BMI at age 25 years (kgm
 2)
a
o21.3 112 0.606
21.3–23.3 91 0.625
23.4+ 96 0.601 0.63
BMI at age 45 years (kgm
 2)
b
o23.0 110 0.604
23.0–25.3 97 0.626
25.4+ 91 0.603 0.60
Smoking
Never 74 0.643
Past 175 0.615
Current 51 0.556 0.01
Cigarettesday
 1c
o20 24 0.599
20+ 27 0.520 0.06
Social class
I, II, III nonmanual 167 0.624
III manual, IV, V 133 0.595 0.15
aOne control had missing data.
bTwo controls had missing data.
cAmong current
smokers only.
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cigarettes or more per day had 13% lower levels than men who
smoked less than 20 cigarettes per day, although this difference
was not statistically significant (P¼0.06). Age, body mass index
(BMI; weight (kg)/height (m)
2) at ages 25 and 45 years and social
class were not associated with nail selenium concentration.
Table 2 shows the association of baseline characteristics with
cancer risk among 300 prostate cancer cases and their controls.
Social class was significantly associated with prostate cancer risk;
men in the lower social class group had a 54% increased risk of
developing prostate cancer compared with men in a higher social
class group (OR 1.54; 95% CI, 1.09–2.18). The proportion of men
with a family history of prostate cancer was higher among cases
than controls, although the association was not statistically
significant (OR 2.14; 95% CI, 0.87–5.26). Marital status, smoking
and BMI at age 25 or 45 years were not associated with risk. These
associations are similar to those previously reported in the full
case–control study of 656 subjects (Key et al, 1997).
There was no significant difference in the mean selenium
concentration between cases and controls; the geometric mean was
0.622p.p.m. in cases and 0.611p.p.m. in controls (P¼0.454,
Table 3); adjustment for social class made no appreciable
difference to the means (results not shown). There was also no
significant difference between the geometric mean selenium
concentration in men with localised or advanced cancer and that
of their controls (Table 3), or between men with localised and
advanced disease (P¼0.215).
Details of risk by quartile of nail selenium concentration are
shown in Table 4: overall, no association was found, either before
or after adjustment for social class. Men in the highest quartile had
a nonsignificant increased risk compared with men in the lowest
quartile (OR 1.24; 95% CI, 0.73–2.10). Additional adjustment for
smoking made no difference to the association between selenium
concentration and risk and the association was similar when
current smokers were excluded from the analysis (results not
shown). The test for multiplicative interaction between selenium
concentration (in quartiles) and smoking status was not statisti-
cally significant after including these terms together with the
interaction term into the model (P¼0.169). Additional adjustment
for food items and nutrients found to be associated with prostate
cancer risk in our study of a previous analysis of this study
population, including garlic, beans, peas and vitamin B6 intake
(Key et al, 1997) made no appreciable difference to the risk
estimates and were not included in the final model.
Selenium concentration was not associated with localised or
advanced disease (Table 4). However, men in the highest quartile
of selenium nail concentration had a non-significant 22% reduced
risk of developing advanced prostate cancer compared with men in
the lowest selenium quartile (OR¼0.78; 95% CI, 0.27–2.25).
There was no evidence that vitamin E intake was independently
associated with risk, either before or after adjustment for social
class (OR for vitamin E intake of 12 or more mgday
 1 vs less than
12mgday
 1¼0.85; 95% CI, 0.62–1.17), and there was no evidence
of interaction with selenium concentration on risk (P¼0.729).
DISCUSSION
The findings from this study suggest that selenium concentration,
as measured in fingernail clippings, is not strongly associated with
prostate cancer risk. Although previous studies have assessed the
selenium content in toe nails, which is 9–15% lower than that of
fingernails (Baskett et al, 1995), selenium concentrations in these
British men are still somewhat lower than those reported in North
American populations (Yoshizawa et al, 1998; Ghadirian et al,
2000; Helzlsouer et al, 2000) and are comparable with other
European populations (Kardinaal et al, 1997; van den Brandt et al,
2003). It is well established that the selenium content of European
soils is low and that dietary intake has been gradually declining
due to a reduction in imported selenium-rich wheat from the US
and Canada, together with a general decline in cereal consumption
(Rayman, 1997). Indeed, it is estimated that selenium intake in the
UK has declined by about a third from an average of 60mgday
 1 in
the late 1970s to 30–40mgday
 1 in the late 1990s, which is
approximately half the reference daily intake of 75mgday
 1 for
adult men (Rayman, 1997). Although dietary selenium intake was
not estimated in this study population because of the wide
variation in soil selenium content and the lack of information
about supplemental selenium use, the low nail selenium concen-
trations confirm that dietary intake in British men is indeed lower
than that of typical North American populations.
Our finding that current smokers have lower selenium
levels than never-smokers is consistent with previous studies
Table 2 Association between baseline characteristics and prostate
cancer risk
Cases Controls Odds ratio
(n¼300) (n¼300) (95% CI)
Marital status
a
Married 228 245 1.00
Unmarried 72 55 1.40 (0.95–2.09)
Test for heterogeneity P¼0.11
Smoking status
Never 75 74 1.00
Past 175 175 0.99 (0.66–1.47)
Current 50 51 0.97 (0.59–1.59)
Test for heterogeneity P¼0.90
Family history of prostate cancer
b
No 285 293 1.00
Yes 15 7 2.14 (0.87–5.26)
Test for heterogeneity P¼0.10
Social class
I,II,III nonmanual 139 167 1.00
III manual, IV, V 161 133 1.54 (1.09–2.18)
Test for heterogeneity P¼0.02
BMI at age 25 years (kgm
 2)
o21.3 94 112 1.00
21.3–23.3 113 91 1.45 (0.98–2.15)
23.4+ 91 96 1.14 (0.77–1.69)
Test for linear trend P¼0.53
BMI at age 45 years (kgm
 2)
o23.0 91 110 1.00
23.0–25.3 97 97 1.19 (0.80–1.73)
25.4+ 110 91 1.42 (0.97–2.08)
Test for linear trend P¼0.07
aMarried refers to married or cohabitating men; unmarried refers to single, separated,
divorced or widowed men.
bReporting having had a father or brother with prostate
cancer.
Table 3 Geometric mean nail selenium concentrations in cases and
controls
Cases Controls
Number Mean Number Mean P-value
Total cancer 300 0.622 300 0.611 0.45
Localised 211 0.631 211 0.607 0.17
Advanced 89 0.602 89 0.621 0.47
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1993). However, smoking was not associated with risk in this study
population and additional adjustment for smoking made no
appreciable difference to the association between selenium
concentration and cancer risk.
The hypothesis that selenium and vitamin E intake may interact
to influence prostate cancer risk has been largely derived from
animal studies (Diplock, 1978) and from a randomised controlled
trial that found a-tocopherol to be associated with a reduced risk
of prostate cancer (Heinonen et al, 1998). Indeed, a trial
specifically designed to test the joint efficacy of selenium and
vitamin E for the prevention of prostate cancer is underway (Klein
et al, 2003). Evidence from observational studies has, however,
been inconsistent; although one study found that risk was
lowest among men with both a high selenium and d-tocopherol
level (Helzlsouer et al, 2000), the present study and others
have found no interaction of vitamin E intake and selenium
levels with risk (Hartman et al, 1998; Yoshizawa et al, 1998;
Vogt et al, 2003).
The main strengths of this study are the large number of cases
and controls, the ability to categorise cancers into localised and
advanced disease, and detailed information on potential con-
founding factors. Further, selenium measures based on nail
samples have been shown to reflect selenium intake integrated
over the previous 6–12 months (Morris et al, 1983) and can be
used to rank subjects according to long-term dietary selenium
intake (Longnecker et al, 1996). Moreover, a single measure has
shown moderate reliability over a 6-year period, with a correlation
coefficient of 0.48 (Garland et al, 1993).
The main limitation of this study is the possibility that the
cancer or its treatment may affect nutritional status and thereby
selenium levels. However, as nails reflect nutritional status for up
to a year prior to clipping, any recent changes in nutrient intake or
physiology are unlikely to influence nail concentration over the
short-term. The observation that the mean selenium concentration
was similar between men with localised and advanced disease also
suggests that disease status is unlikely to influence the association
between selenium concentration and prostate cancer risk in this
study population.
In conclusion, the findings from this study suggest that selenium
concentration, as measured in nail clippings, is not strongly
associated with prostate cancer risk in British men. This is in
contrast to the results of the Nutritional Prevention of Cancer trial
that found selenium supplementation to be associated with a
significant reduction in prostate cancer risk (Clark et al, 1996;
Duffield-Lillico et al, 2002). Several prospective studies have also
found significant protective associations for serum or nail
selenium levels in relation to prostate cancer (Yoshizawa et al,
1998; Helzlsouer et al, 2000; Nomura et al, 2000; Brooks et al, 2001;
van den Brandt et al, 2003). However, consistent with the findings
from the present study, some other observational studies have
failed to find such an association (Willett et al, 1983; Coates et al,
1988; Knekt et al, 1990; Hardell et al, 1995; Ghadirian et al, 2000;
Goodman et al, 2001; Vogt et al, 2003). It is unclear whether these
epidemiological data overall are or are not supportive of a
reduction in prostate cancer risk with high selenium intake, and a
pooled analysis might be informative.
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